A Comprehensive Monograph on Ferric Pyrophosphate Citrate (Triferic®, Triferic AVNU®): A Novel Parenteral Iron for Hemodialysis-Dependent Chronic Kidney Disease

1.0 Executive Summary

Ferric Pyrophosphate Citrate (FPC) is a novel, small-molecule iron replacement product specifically engineered for the management of anemia in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). Marketed under the brand names Triferic® and Triferic AVNU®, FPC represents a significant departure from traditional carbohydrate-based intravenous (IV) iron therapies. Its fundamental distinction lies in its chemical structure—a water-soluble, non-colloidal complex iron salt that contains no carbohydrate shell. This unique composition enables a novel mechanism of action: the direct and immediate donation of iron to circulating transferrin, thereby bypassing the reticuloendothelial system (RES) where conventional IV irons are processed.

This physiological pathway offers several key therapeutic advantages. By circumventing the RES, FPC avoids the inflammatory-mediated sequestration of iron by macrophages, a process governed by the hormone hepcidin, which is typically elevated in the chronic inflammatory state of CKD. This allows for more efficient iron utilization for erythropoiesis. Furthermore, the slow, continuous administration during each hemodialysis session is designed to replace the precise amount of iron lost during the procedure (approximately 5-7 mg), mimicking natural iron absorption and maintaining hemoglobin levels without causing a significant increase in ferritin, a marker of stored iron and inflammation.

Clinically, FPC is indicated for the replacement of iron to maintain hemoglobin in adult HDD-CKD patients. Its efficacy has been established in pivotal clinical trials, which demonstrated its ability to maintain hemoglobin while significantly reducing the required dose of erythropoiesis-stimulating agents (ESAs)—a critical benefit given the safety concerns associated with high-dose ESA therapy.

FPC is available in two distinct formulations to accommodate different clinical workflows: Triferic®, a solution or powder added to the hemodialysate, and Triferic AVNU®, a solution for direct intravenous infusion during the dialysis session. The safety profile is characterized by common adverse events typical of the hemodialysis population, such as procedural hypotension and muscle spasms. The most significant risk is the potential for serious hypersensitivity reactions, a known class effect for all parenteral iron products, which necessitates careful patient monitoring. Notably, FPC does not carry an FDA Black Box Warning.

The global regulatory landscape for FPC is highly focused on the United States, where it holds strong approvals from the Food and Drug Administration (FDA). Its presence in other major markets is limited or follows different regulatory pathways, such as its classification as an over-the-counter product in Japan and its inclusion as an ingredient in listed supplements in Australia. This monograph provides an exhaustive analysis of FPC's chemical properties, pharmacology, clinical development, therapeutic use, and regulatory status, positioning it as a specialized and mechanistically innovative tool in the armamentarium for managing anemia in the HDD-CKD population.

2.0 Compound Identification and Physicochemical Profile

A comprehensive understanding of Ferric Pyrophosphate Citrate begins with its fundamental chemical identity and physical properties, which are the basis for its unique pharmacological behavior and clinical application.

2.1 Chemical Identifiers

Ferric Pyrophosphate Citrate is identified across scientific literature, regulatory filings, and chemical databases by a variety of names and codes. Establishing these identifiers is crucial for accurate data retrieval and cross-referencing. The compound is a small molecule drug.[1]

• Generic Name: Ferric pyrophosphate citrate [1]
• Brand Names (US): Triferic®, Triferic AVNU® [2]
• Common Synonyms: FPC, Soluble ferric pyrophosphate, SFP, Dialysate Triferic, Tetraferric nonahydrogen citrate pyrophosphate [6]
• DrugBank ID: DB13995 [7]
• CAS Number: 1802359-96-1 [7]
• UNII (Unique Ingredient Identifier): UBY79OCO9G [7]
• KEGG ID: D10933 [9]
• RXCUI: 1607975 [9]

2.2 Molecular and Structural Characteristics

The molecular structure of FPC is central to its mechanism of action and differentiates it from other parenteral iron therapies.

• Molecular Formula: C18​H24​Fe4​O42​P6​ [7]
• Molecular Weight: 1321.6 g/mol [7]
• IUPAC Name: hydron;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);phosphonato phosphate [9]

Structurally, FPC is a non-colloidal, complex iron salt.[14] X-ray absorption spectroscopy data reveal that it consists of an iron (III) cation complexed with one pyrophosphate molecule and two citrate molecules in its solid state, a structure that is preserved in solution.[14] The ferric ion is strongly complexed by these pyrophosphate and citrate ligands, which provides stability and prevents the premature release of free, potentially toxic iron.[7]

A critical structural feature is the absence of a carbohydrate shell.[14] This is a defining difference from many conventional IV iron preparations (e.g., iron sucrose, iron dextran), which are colloidal nanoparticles consisting of an iron oxyhydroxide core surrounded by a carbohydrate moiety. This structural distinction is the direct determinant of FPC's unique physiological pathway, as it does not require processing by the macrophages of the reticuloendothelial system (RES) to release its iron cargo.[14] FPC is a pharmaceutical-grade compound with higher solubility and better characterization than older, food-grade soluble ferric pyrophosphate (SFP) compounds from which it was developed.[14]

It is also essential to distinguish Ferric Pyrophosphate Citrate (Triferic®) from a separate entity, "ferric citrate coordination complex." The latter was approved in the European Union under the brand name Fexeric® for the treatment of hyperphosphatemia, an authorization that has since lapsed.[16] A new product based on ferric citrate coordination complex, Xoanacyl®, recently received a positive opinion for the dual indication of hyperphosphatemia and iron deficiency in CKD.[18] These compounds are chemically and therapeutically distinct from FPC, which is indicated solely for iron replacement in HDD-CKD.

2.3 Physical and Chemical Properties

The physical properties of FPC are well-suited for its intended pharmaceutical application.

• Appearance: It is described as a yellow to green or apple green to greenish-brown, free-flowing, amorphous powder.[7]
• Solubility: FPC is freely soluble in water (>100 g/L) but is insoluble in most organic solvents (e.g., methanol, acetone, DMSO).[7] This high aqueous solubility is essential for its formulation as a solution for IV infusion or for dilution into aqueous bicarbonate concentrate for hemodialysis.
• pH: A 5% solution of FPC in water has a pH of approximately 6.[8]
• Thermal Properties: The substance does not melt below 300 °C, with thermal decomposition observed at 263±3 °C.[8]

The following table consolidates the key identifiers and physicochemical properties of Ferric Pyrophosphate Citrate for ease of reference.

Table 1: Key Identifiers and Physicochemical Properties of Ferric Pyrophosphate Citrate

Property	Value	Source(s)
Generic Name	Ferric pyrophosphate citrate	1
Brand Names	Triferic®, Triferic AVNU®	2
Synonyms	FPC, Soluble ferric pyrophosphate (SFP), Triferic	6
DrugBank ID	DB13995	7
CAS Number	1802359-96-1	9
UNII	UBY79OCO9G	7
Molecular Formula	C18​H24​Fe4​O42​P6​	7
Molecular Weight	1321.6 g/mol	7
IUPAC Name	hydron;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);phosphonato phosphate	9
Appearance	Apple green to greenish-brown, free-flowing powder	7
Solubility	Freely soluble in water; insoluble in alcohol and most organic solvents	7

3.0 Pharmacology and Mechanism of Action

The pharmacological profile of Ferric Pyrophosphate Citrate is defined by its novel and highly physiological mechanism of iron delivery, which distinguishes it from all other parenteral iron therapies.

3.1 Primary Mechanism: Direct Iron Donation to Transferrin

The core mechanism of FPC is the direct, immediate, and complete donation of its iron cargo to apo-transferrin (the iron-free form of the body's primary iron transport protein) upon entering the bloodstream.[10] The strong complexation between the ferric ion (

Fe3+) and its citrate and pyrophosphate ligands ensures the iron remains stably bound and protected until this transfer occurs, preventing the release of free, redox-active iron into the plasma.[7] Kinetic analyses and crystallographic studies have confirmed that FPC can rapidly donate iron to both iron-binding sites within the transferrin protein structure.[21] This process is remarkably efficient, allowing the newly bound iron to be transported directly to erythroid precursor cells in the bone marrow for incorporation into hemoglobin.[1]

3.2 Bypassing the Reticuloendothelial System (RES) and Hepcidin Block

This mechanism of direct donation to transferrin allows FPC to completely bypass the reticuloendothelial system (RES).[15] Conventional carbohydrate-based IV iron products are nanoparticles that are taken up by macrophages in the RES (primarily in the liver and spleen). The iron must then be processed and released from these macrophages to become available for erythropoiesis.[15] This release is tightly regulated by hepcidin, a peptide hormone that is the master regulator of iron homeostasis.

Patients with chronic kidney disease exist in a state of persistent inflammation, which leads to pathologically elevated levels of hepcidin.[15] High hepcidin levels block the export of iron from macrophages, effectively trapping iron within the RES and leading to a state known as functional iron deficiency, where iron stores (measured by ferritin) may be adequate or high, but iron is not available for red blood cell production.[15] By delivering iron directly to transferrin in the circulation, FPC effectively circumvents this hepcidin-mediated block.[15] This "hepcidin bypass" is arguably FPC's most significant pharmacological advantage, making it a theoretically superior option for delivering usable iron in the inflammatory milieu of HDD-CKD.

3.3 Physiological Consequences and Therapeutic Advantages

The unique mechanism of FPC translates into several distinct therapeutic advantages, positioning its use as a paradigm shift from high-dose iron "repletion" to low-dose, physiological "maintenance."

• Reduced Oxidative Stress: Free, non-transferrin-bound iron (NTBI) is highly toxic, as it can catalyze the formation of free radicals, leading to lipid peroxidation and cellular damage.[7] The rapid and direct transfer of iron from FPC to transferrin minimizes the presence of NTBI in the circulation, thereby reducing the potential for oxidative stress and inflammation that can be associated with other IV iron formulations.[15]
• Physiologic Iron Delivery: FPC is administered slowly and continuously during every 3-to-4-hour hemodialysis session. This method is designed to replace the 5-7 mg of iron that is obligatorily lost during each treatment.[20] This approach mimics the body's natural, gradual absorption of dietary iron, contrasting sharply with the large, infrequent bolus doses of traditional IV iron, which can overwhelm transferrin's binding capacity and lead to iron deposition in storage tissues.[20]
• Maintenance of Hemoglobin without Iron Overload: Clinical studies have shown that FPC effectively maintains hemoglobin levels while avoiding significant increases in serum ferritin.[20] In the context of CKD, high ferritin is not only a marker of iron stores but also an acute-phase reactant that reflects inflammation. By maintaining iron balance without driving up ferritin levels, FPC helps prevent iron overload in the liver and other tissues and avoids confounding the interpretation of inflammatory markers.[20]

3.4 Target Protein Binding

The ultimate targets for the iron delivered by FPC are the proteins involved in iron transport and utilization. Upon donation to transferrin, the iron is delivered to the bone marrow for incorporation into hemoglobin subunits alpha and beta, facilitating the synthesis of new red blood cells.[1] The FPC molecule itself is also described as a binder of ferritin light and heavy chains, reflecting its intimate involvement in the iron metabolic pathway.[1]

4.0 Pharmacokinetic Profile (ADME)

The pharmacokinetic profile of Ferric Pyrophosphate Citrate—its absorption, distribution, metabolism, and excretion (ADME)—is intrinsically linked to its unique mechanism of action and dictates its specific dosing and administration strategy.

4.1 Absorption and Bioavailability

When administered intravenously, either directly as Triferic AVNU® or via the dialysate as Triferic®, the iron from FPC is delivered directly into the systemic circulation. This route of administration ensures very high bioavailability, reported to be between 83-94%.[1] Pharmacokinetic studies in healthy volunteers have demonstrated a dose-dependent response. Following a 4-hour IV infusion of doses ranging from 2.5 to 10 mg, the maximum serum concentration (

Cmax​) ranged from 113 to 261 mcg/dL, and the area under the curve (AUC) ranged from 675 to 1840 mcg·hr/dL.[1] The time to reach maximum concentration (

Tmax​) is approximately 4.5 hours.[1]

4.2 Distribution

Upon entering the circulation, FPC is rapidly cleared as its iron is bound by transferrin.[15] The drug exhibits a small apparent volume of distribution (

Vd​), which after a 4-hour IV infusion ranged from 0.765 to 0.859 L.[9] This low value indicates that the compound does not distribute extensively into tissues and remains primarily within the vascular compartment, consistent with its function of delivering iron directly to the plasma protein transferrin.

4.3 Metabolism

The metabolism of iron delivered by FPC is analogous to the physiological processing of endogenous iron absorbed from the gut.[1] A key feature is that it does not require prior metabolism by the reticuloendothelial system.[1] The iron is immediately available to bind to transferrin and can be transported for direct incorporation into hemoglobin or, to a lesser extent, delivered to ferritin for storage without the need for intermediate processing by macrophages.[1]

4.4 Excretion and Half-Life

The pharmacokinetic profile of FPC is characterized by rapid clearance and a short half-life, a property that is perfectly suited for its administration during intermittent hemodialysis. The terminal elimination half-life (t1/2​) is approximately 1.48 hours.[1] This ensures that the drug is largely cleared from the plasma within the timeframe of a single dialysis session, preventing accumulation with repeated dosing. The mean clearance rate (CL) from the plasma ranges from 0.406 to 0.556 L/hour.[1]

Similar to endogenous iron, the body has no active physiological mechanism for excreting excess iron. The iron delivered by FPC is highly retained and conserved. In the absence of bleeding, iron loss is minimal and occurs primarily through the shedding of cells from the skin and gastrointestinal tract, as well as in small amounts in sweat, urine, hair, and nails.[1]

The table below summarizes the key pharmacokinetic parameters for FPC.

Table 2: Summary of Key Pharmacokinetic Parameters for Ferric Pyrophosphate Citrate

Parameter	Value	Notes / Conditions	Source(s)
Bioavailability	83-94%	Intravenous / Dialysate administration	1
Cmax​ (Maximum Concentration)	113-261 mcg/dL	Dose-dependent (2.5 to 10 mg IV dose over 4 hours)	1
AUC (Area Under the Curve)	675-1840 mcg·hr/dL	Dose-dependent (2.5 to 10 mg IV dose over 4 hours)	1
Tmax​ (Time to Cmax​)	~4.5 hours	Following IV infusion	1
Volume of Distribution (Vd​)	0.765 - 0.859 L	Following 4-hour IV infusion	9
Clearance (CL)	0.406 - 0.556 L/hour	Mean clearance rate	1
Half-life (t1/2​)	1.48 hours	Terminal elimination half-life	1

5.0 Clinical Development and Efficacy

The clinical development program for Ferric Pyrophosphate Citrate was strategically designed to demonstrate its efficacy and safety specifically within its target population of adult patients with hemodialysis-dependent chronic kidney disease.

5.1 Pivotal Phase 3 Trials (CRUISE 1 & 2)

The foundation of FPC's approval rests on two pivotal, randomized, placebo-controlled, multicenter Phase 3 clinical trials: CRUISE 1 (NCT01320202) and CRUISE 2 (NCT01322347).[25] These studies evaluated the safety and efficacy of FPC solution administered via hemodialysate for up to one year. A total of 292 patients received FPC, with a mean treatment exposure of 5 months in the randomized period.[25] The results of these trials were positive, demonstrating that patients treated with FPC were significantly more likely to maintain their hemoglobin levels within predefined target ranges compared to patients receiving placebo.[23] This confirmed that FPC was capable of effectively replacing the iron losses that occur due to hemodialysis and uremia.[23]

5.2 Key Efficacy Endpoint: Reduction in ESA Use

A primary objective and a major value driver of the FPC clinical program was to demonstrate a reduction in the use of erythropoiesis-stimulating agents (ESAs). High doses of ESAs are associated with significant safety risks, including cardiovascular events, making any therapy that can lower the required dose highly desirable. The PRIME study, a key trial in the development program, explicitly tested this endpoint.[28]

In this study, patients treated with FPC showed a statistically significant 35% reduction in their prescribed ESA dose from baseline to the end of treatment, compared to patients on placebo.[28] This ESA-sparing effect was achieved while successfully maintaining hemoglobin levels. Furthermore, the FPC-treated group required 51% less supplemental IV iron than the placebo group, underscoring its efficacy as a maintenance iron therapy.[28] The ability to maintain hemoglobin while reducing the need for both ESAs and conventional IV iron is a central pillar of FPC's clinical value proposition.[1]

5.3 Development for Other Indications

The manufacturer explored the potential of FPC beyond the HDD-CKD population, though with limited success. A Phase 1 clinical trial (NCT02767128) was completed to assess the pharmacokinetics and absolute bioavailability of an oral formulation of FPC in healthy volunteers.[29] This suggests an early interest in developing FPC as a potential oral iron supplement.

However, a more ambitious Phase 2 trial (NCT02905981) designed to evaluate FPC for the treatment of Iron-Refractory Iron-Deficiency Anemia (IRIDA) was terminated.[6] IRIDA is a rare genetic disorder characterized by high hepcidin levels, making it a logical target for a drug designed to bypass the hepcidin block. The termination of this trial suggests that FPC either did not demonstrate sufficient efficacy in this non-dialysis population or that a strategic decision was made to focus resources on the core HDD-CKD indication where its benefits were most clearly established.

5.4 Ongoing and Post-Marketing Studies

Clinical investigation into FPC and related formulations continues. A Phase 2 study (NCT05110768) is evaluating an infused FPC formulation for treating iron deficiency anemia in patients receiving home infusion therapy.[6] Additionally, a Phase 3 trial (CTRI/2022/06/042974) was initiated in India to evaluate FPC administered via dialysate in HDD-CKD patients.[6] A Phase 4 study investigating a micronized microencapsulated ferric pyrophosphate (MMFP) for iron deficiency anemia has also been completed, indicating ongoing research into novel oral delivery technologies for related compounds.[6]

6.0 Approved Indications and Therapeutic Use

The clinical application of Ferric Pyrophosphate Citrate is precisely defined by its regulatory approvals, which establish its specific role in managing anemia in a targeted patient population.

6.1 FDA-Approved Indication

Both Triferic® and Triferic AVNU® are approved by the U.S. Food and Drug Administration (FDA) for the same indication: for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).[2] This indication positions FPC not as a first-line agent for correcting severe iron deficiency from a depleted state, but as a maintenance therapy designed to proactively counteract the ongoing, predictable iron losses associated with the hemodialysis procedure itself.

6.2 Limitations of Use

The FDA-approved prescribing information contains explicit and critical limitations that narrowly define the patient population for which FPC is intended. These limitations are consistently highlighted across all labeling and are crucial for safe and effective use:

• Not for Peritoneal Dialysis: Triferic® and Triferic AVNU® are not intended for use in patients receiving peritoneal dialysis.[5] The drug's delivery mechanism is intrinsically linked to the hemodialysis circuit.
• Not Studied in Home Hemodialysis: The drug has not been studied in patients receiving home hemodialysis.[5] This confines its approved use to the in-center hemodialysis setting.

These limitations underscore that FPC is a highly specialized product designed for a specific care environment. This was a point of regulatory scrutiny, as evidenced by a warning letter from the FDA's Office of Prescription Drug Promotion (OPDP) issued to the manufacturer.[34] The letter cited marketing materials that omitted these limitations, creating a potentially misleading impression that Triferic® was indicated for a broader dialysis population. The FDA also challenged claims that Triferic® was "safer or more effective" than other IV iron products or that it "prevents iron induced liver damage," stating that such claims of superiority were not supported by the submitted clinical trial data.[34] This regulatory action emphasizes the importance of adhering to the precise, narrow indication.

6.3 Clinical Context and Patient Selection

In clinical practice, FPC is used to maintain iron balance in stable HDD-CKD patients. Some healthcare payers have established specific criteria for its use to ensure it is prescribed appropriately. For instance, coverage policies may require documentation of medical necessity, such as a transferrin saturation (TSAT) of ≤ 30% and a serum ferritin level of ≤ 500 ng/mL.[5] Furthermore, some policies may require a trial and failure of, or contraindication to, other conventional IV iron products like sodium ferric gluconate complex (Ferrlecit®) and iron sucrose (Venofer®) before approving FPC.[5] This can position FPC as a second-line or specialized maintenance therapy in certain healthcare systems, reserved for patients who do not respond adequately to or cannot tolerate traditional iron repletion agents.

7.0 Commercial Formulations, Dosage, and Administration

Ferric Pyrophosphate Citrate is marketed in two distinct commercial formulations, a strategic approach designed to maximize its accessibility across different hemodialysis clinic infrastructures. Both formulations deliver iron during the hemodialysis session but via different routes of administration.

7.1 Triferic® (for Hemodialysate Administration)

This formulation is designed to be integrated directly into the hemodialysis process.

• Formulations: Triferic® is available as:
• A sterile solution in single-dose 5 mL ampules, containing 27.2 mg of iron (III) at a concentration of 5.44 mg/mL.[5]
• A powder for solution in single-use packets, containing 272 mg of iron (III) per packet.[5]
• Administration: This formulation must be diluted prior to administration by adding it exclusively to the liquid bicarbonate concentrate used for generating hemodialysate.[7] It must not be added to the acid concentrate mixture. The dilution is standardized to achieve a final concentration of 2 micromolar (110 mcg/L) of iron (III) in the final dialysate that circulates through the dialyzer.[32] During the dialysis session, the iron from the dialysate passively crosses the dialyzer membrane into the patient's blood, providing slow, continuous iron delivery.[15] This method is most suitable for dialysis centers that utilize a central liquid bicarbonate distribution system.

7.2 Triferic AVNU® (for Intravenous Infusion)

This formulation was developed to provide an alternative for clinics where administration via dialysate is not feasible, such as those using solid bicarbonate cartridges.

• Formulation: Triferic AVNU® is a sterile solution for injection provided in a single-dose luer-lock ampule. Each 4.5 mL ampule contains 6.75 mg of iron (III) at a concentration of 1.5 mg/mL.[5]
• Administration: The entire contents of the ampule (6.75 mg of iron) are administered undiluted as a slow, continuous intravenous infusion over 3 to 4 hours.[25] The infusion is given concurrently with the hemodialysis treatment. It can be administered via the pre-dialyzer infusion line, the post-dialyzer infusion line, or a separate connection to the venous blood line.[25] This direct IV route provides flexibility and expands access to FPC therapy.

7.3 Dosing Regimen

Regardless of the formulation used, the therapeutic principle is the same: to provide consistent iron replacement. Therefore, FPC is administered at each hemodialysis procedure for as long as the patient requires maintenance hemodialysis therapy.[20] The typical dose delivered per session via the intravenous route (Triferic AVNU®) is 6.75 mg of elemental iron.[5] This frequency and low dose are central to the drug's "physiologic maintenance" philosophy.

The following table provides a clear comparison of the two commercial formulations.

Table 3: Comparison of Commercial Formulations: Triferic® vs. Triferic AVNU®

Feature	Triferic®	Triferic AVNU®
Formulation Type	Solution or Powder	Solution for Injection
Available Strengths	Solution: 27.2 mg/5 mL ampule Powder: 272 mg/packet	6.75 mg/4.5 mL luer-lock ampule
Route of Administration	Addition to hemodialysate (via bicarbonate concentrate)	Intravenous (IV) infusion
Dosing Regimen	Administered at each hemodialysis session	6.75 mg IV infused over 3-4 hours at each hemodialysis session
Preparation	Must be diluted in bicarbonate concentrate prior to use	Administered undiluted
Intended Clinical Setting	Dialysis clinics with liquid bicarbonate distribution systems	All hemodialysis clinics, including those using solid bicarbonate cartridges

8.0 Safety and Tolerability Profile

The safety profile of Ferric Pyrophosphate Citrate has been well-characterized through its clinical development program. While it shares some risks common to all parenteral iron products, its overall profile is considered acceptable for its indicated population.

8.1 Common Adverse Reactions

The most common adverse reactions observed in the pivotal placebo-controlled clinical trials (CRUISE 1 and CRUISE 2) are largely consistent with events commonly seen in the hemodialysis population. Adverse reactions reported with an incidence of ≥3% in patients receiving FPC and at a rate at least 1% greater than placebo include [25]:

• Procedural hypotension: 22%
• Muscle spasms: 10%
• Headache: 9%
• Peripheral edema: 7%
• Pain in extremity: 7%
• Dyspnea (shortness of breath): 6%
• Urinary tract infection: 5%
• Pyrexia (fever): 5%
• Back pain: 5%
• Asthenia (weakness/lack of energy): 4%
• Fatigue: 4%
• Arteriovenous fistula thrombosis: 3%
• Arteriovenous fistula site hemorrhage: 3%

Adverse reactions that led to treatment discontinuation in some patients included headache, asthenia, dizziness, nausea, pruritus, and hypersensitivity reactions.[25]

8.2 Serious Warnings and Precautions: Hypersensitivity Reactions

The most significant safety concern associated with FPC is the risk of serious hypersensitivity reactions, including anaphylactic-type reactions, which can be life-threatening and fatal.[8] This is a known class effect for all parenteral iron products. The prescribing information mandates that patients should be monitored for signs and symptoms of hypersensitivity (e.g., rash, hypotension, dyspnea, collapse) during and after the hemodialysis session until they are clinically stable. Furthermore, personnel and therapies for the immediate treatment of serious hypersensitivity reactions must be readily available whenever FPC is administered.[25]

While this warning is prominent, the risk should be contextualized. The reported incidence of hypersensitivity reactions in the primary clinical trials was very low, occurring in only 0.3% of patients treated with FPC.[35] The manufacturer has also stated that no reports of anaphylaxis occurred in over 1,000,000 administrations of the commercial product.[22]

8.3 Lack of Black Box Warning

A crucial aspect of FPC's safety profile is that it does not have an FDA Black Box Warning.[25] This is a significant differentiator in the therapeutic area of anemia of CKD. Erythropoiesis-stimulating agents (ESAs), which are often used concomitantly, carry a prominent black box warning regarding an increased risk of death, myocardial infarction, stroke, and other serious cardiovascular events when hemoglobin levels are targeted to higher levels.[44] The absence of such a warning for FPC allows it to be positioned as a safer therapeutic partner, particularly given its demonstrated ability to reduce the required dose of these black-boxed agents.

8.4 Use in Specific Populations

• Pregnancy: There are no adequate and well-controlled studies of FPC use in pregnant women. Animal reproduction studies in rats and rabbits showed adverse developmental outcomes (e.g., post-implantation loss, decreased fetal body weight, fetal malformations) only at maternally toxic doses that were significantly higher than the maximum recommended human dose.[25] The prescribing information advises that FPC be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Females of reproductive potential are advised to use effective contraception during treatment and for at least 2 weeks after the final dose.[27]
• Lactation: There are no data on the presence of FPC in human milk, its effects on the breastfed child, or its effects on milk production. A decision to use the drug while breastfeeding should weigh the potential benefits against the potential risks.[3]
• Pediatric Use: The safety and efficacy of FPC have not been established in pediatric patients (under 18 years of age).[3]
• Geriatric Use: Clinical trials included a substantial number of patients aged 65 and over. No overall differences in safety or efficacy were observed between these older patients and younger patients.[3]

8.5 Contraindications

FPC is contraindicated in patients with a known hypersensitivity to the drug or any of its components.[8] It is also not recommended for use in patients with anemia that is not caused by iron deficiency or in patients with evidence of iron overload (e.g., hemochromatosis).[3]

Table 4: Summary of Common and Serious Adverse Reactions with Ferric Pyrophosphate Citrate

System Organ Class	Adverse Reaction	Incidence in FPC Group (%)	Notes / Severity
General / Administration Site	Peripheral edema	7%	Common
	Pyrexia (Fever)	5%	Common
	Asthenia / Fatigue	4%	Common
Cardiovascular	Procedural hypotension	22%	Very Common
	Arteriovenous fistula thrombosis	3%	Common
	Arteriovenous fistula site hemorrhage	3%	Common
Nervous System	Headache	9%	Common
Musculoskeletal	Muscle spasms	10%	Common
	Pain in extremity	7%	Common
	Back pain	5%	Common
Respiratory	Dyspnea	6%	Common
Infections	Urinary tract infection	5%	Common
Immune System	Hypersensitivity / Anaphylaxis	0.3%	Serious, Potentially Life-Threatening

9.0 Drug and Disease Interactions

The potential for interactions with other drugs or co-existing disease states is an important consideration in the safe use of Ferric Pyrophosphate Citrate, particularly given the high degree of polypharmacy in the chronic kidney disease population.

9.1 Drug-Drug Interactions

Interactions with FPC primarily involve mechanisms that can reduce its efficacy or the efficacy of co-administered drugs.

• Absorption-Related and Chelation Interactions: Although FPC is administered parenterally, thereby bypassing gastrointestinal absorption, interactions based on chelation can still be clinically relevant.
• Other Iron Products: Co-administration of FPC with any other iron-containing product (e.g., ferrous sulfate, iron dextran, iron sucrose) can lead to competitive binding and may decrease the efficacy of FPC. It can also increase the risk of iron overload.[1] Patients should not take other iron supplements unless specifically directed by their provider.[33]
• Chelating Agents and Divalent/Trivalent Cations: Substances that bind to iron can reduce its availability. This includes certain antibiotics like tetracyclines (e.g., minocycline, doxycycline) and fluoroquinolones (e.g., ciprofloxacin, delafloxacin), as well as medications containing calcium, magnesium, or aluminum (e.g., certain phosphate binders and antacids).[3] While primarily an issue for oral iron, the potential for interaction warrants clinical consideration.
• Other Medications: FPC may decrease the absorption and serum concentration of drugs such as carbidopa, cefdinir, and dolutegravir.[51] Dimercaprol may increase the nephrotoxic potential of FPC.[51]
• Target-Mediated Pharmacodynamic Interactions: As FPC delivers iron that ultimately binds to hemoglobin and ferritin, it may have pharmacodynamic interactions with other drugs that act on these same targets. The DrugBank database indicates potential interactions with other hemoglobin subunit binders such as voxelotor, oxygen, and sodium ferric gluconate complex.[24]
• Food Interactions: Foods rich in phytic acid (e.g., whole grains, legumes) are known to inhibit the absorption of oral iron.[3] While this is not a direct interaction for parenterally administered FPC, it is relevant for the patient's overall iron status and dietary management.

9.2 Disease Interactions

The use of FPC is specifically limited by certain co-existing medical conditions or treatment modalities.

• Peritoneal Dialysis: As stated in the FDA's Limitations of Use, FPC is not intended for patients receiving peritoneal dialysis.[36] This is a significant disease-state interaction, as the drug's delivery system is designed for the hemodialysis circuit.
• Iron Overload and Non-Iron-Deficiency Anemias: FPC is an iron replacement product and should not be used in patients who already have excess iron stores (e.g., hemochromatosis) or in patients whose anemia is not caused by iron deficiency.[3] Use in these populations would be inappropriate and could lead to iron toxicity.

10.0 Global Regulatory Landscape

The regulatory status of Ferric Pyrophosphate Citrate varies significantly across major global markets, reflecting different regulatory priorities, clinical needs, and commercial strategies. The product has achieved its greatest success in the United States, while its presence elsewhere is either limited, indirect, or non-existent as a prescription therapy for HDD-CKD.

10.1 United States (FDA)

The United States represents the primary market for FPC, where it has secured approval for two distinct formulations under the parent brand Triferic®.

• Triferic® (for Hemodialysate): The initial formulation received approval from the U.S. Food and Drug Administration (FDA) on January 24, 2015.[1]
• Triferic AVNU® (for Intravenous Use): The intravenous formulation was approved by the FDA on March 27, 2020, expanding the drug's accessibility to a broader range of hemodialysis clinics.[22]

Both formulations are approved for the same indication: the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.

10.2 Europe (EMA)

The regulatory situation in the European Union is more complex and requires careful distinction between different iron compounds.

• Ferric Pyrophosphate Citrate (Triferic®): There is no evidence of a marketing authorisation for FPC for the treatment of anemia in HDD-CKD in the EU. The European Medicines Agency (EMA) has agreed to a paediatric investigation plan (PIP) for FPC, which is a required step for developing drugs for children but does not constitute an approval for marketing.[9]
• Distinction from "Ferric Citrate Coordination Complex": It is imperative to differentiate FPC from a separate but similarly named compound. A "ferric citrate coordination complex" was granted marketing authorisation by the EMA in September 2015 under the brand name Fexeric® for the treatment of hyperphosphatemia in CKD patients.[17] However, this authorisation lapsed on January 13, 2020, because the product was never marketed in the EU.[16] More recently, a product named Xoanacyl®, also a ferric citrate coordination complex, received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) in March 2025 and was granted marketing authorization in June 2025 for the dual treatment of hyperphosphatemia and iron deficiency in adult CKD patients.[18] These products are chemically, indication-wise, and regulatorily distinct from FPC (Triferic®).

10.3 Australia (TGA)

In Australia, there is no evidence that Ferric Pyrophosphate Citrate is approved as a prescription medicine for the treatment of anemia in HDD-CKD. A search of the Therapeutic Goods Administration (TGA) Australian Register of Therapeutic Goods (ARTG) indicates that "ferric pyrophosphate" is permitted as an active ingredient in some "Listed" medicines.[58] Listed medicines are considered lower-risk products (e.g., vitamins, supplements) and are not evaluated by the TGA for efficacy. An example is a product named "IRON GUMMIES" (ARTG ID 464658), which contains ferric pyrophosphate.[59] This regulatory status is fundamentally different from that of a registered prescription drug.

10.4 Japan

In Japan, Ferric Pyrophosphate Citrate is categorized as a second-class Over-The-Counter (OTC) drug.[1] This classification is for drugs with ingredients that, in rare cases, may cause health problems. This indicates a different risk assessment and market access pathway compared to the prescription-only status in the United States.

The following table summarizes the global regulatory status of FPC.

Table 5: Global Regulatory Status Summary for Ferric Pyrophosphate Citrate

Region / Body	Product Name(s)	Approval Status	Approved Indication(s)	Key Notes
United States (FDA)	Triferic®, Triferic AVNU®	Approved	Replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent CKD.	Prescription-only medicine. Initial approval in 2015, with IV formulation approved in 2020.
European Union (EMA)	Ferric pyrophosphate citrate	Not Approved	N/A	A Paediatric Investigation Plan (PIP) is in place, but this is not a marketing authorisation. Must be distinguished from "ferric citrate coordination complex" (Fexeric/Xoanacyl).
Australia (TGA)	N/A (as prescription)	Not Approved (as prescription)	N/A (as prescription)	"Ferric pyrophosphate" is permitted as an ingredient in lower-risk, non-prescription "Listed" medicines (e.g., supplements).
Japan	Ferric pyrophosphate citrate	Approved as OTC	Iron deficiency	Categorized as a second-class Over-The-Counter (OTC) drug.

11.0 Synthesis and Expert Analysis

Ferric Pyrophosphate Citrate (Triferic®/Triferic AVNU®) represents a targeted and mechanistically distinct innovation in the management of anemia for a highly specific patient population. Its clinical and commercial profile is best understood through a comparative lens, recognizing its unique role within the broader landscape of iron replacement therapies.

11.1 Comparative Analysis: FPC vs. Traditional Parenteral Irons

FPC's primary differentiation from conventional carbohydrate-based IV iron agents (e.g., iron sucrose, ferric gluconate, iron dextran) stems from its fundamental chemistry and resulting pharmacology. This creates a series of clinical trade-offs.

• Mechanism and Physiology: Traditional IV irons are nanoparticles requiring RES processing, making them susceptible to the hepcidin-mediated iron block prevalent in the inflammatory state of CKD. FPC's direct donation of iron to transferrin bypasses this block, offering a more direct and potentially more efficient route to erythropoiesis in inflamed patients. This physiologic delivery, which mimics the slow replacement of dialytic losses, contrasts with the high-dose bolus approach of other agents, which aims to replete storage iron (ferritin).
• Safety Profile: By minimizing the generation of non-transferrin-bound iron (NTBI), FPC may offer a superior safety profile with respect to oxidative stress and inflammation. While it shares the class-wide risk of hypersensitivity reactions, the lack of a Black Box Warning is a significant advantage over ESAs, a common co-therapy.
• Clinical Application and Flexibility: The key limitation of FPC is its lack of flexibility. Its use is confined to the in-center hemodialysis population and requires administration with every single treatment. Traditional IV irons, conversely, can be used for high-dose repletion in a wide variety of clinical settings (inpatient, outpatient, non-dialysis CKD, etc.) with more flexible dosing schedules (e.g., weekly or monthly).

This analysis reveals that FPC is not a direct replacement for traditional IV irons but rather a specialized tool. The decision to terminate its development for IRIDA suggests a recognition that its primary value is realized in the unique pathophysiological niche of HDD-CKD, where ongoing iron loss and high inflammation are defining features.

11.2 The Role of FPC in Modern Anemia Management in CKD

The optimal role for FPC is in the maintenance phase of anemia management for stable adult HDD-CKD patients. It is ideally suited to proactively maintain iron homeostasis, prevent the gradual decline of hemoglobin, and, critically, minimize patient exposure to both high-dose ESAs and large bolus doses of IV iron. Its ESA-sparing effect directly addresses a major safety concern in modern nephrology, driven by the black box warnings on the ESA class.

Therefore, FPC complements, rather than competes with, traditional repletion agents. A new patient presenting with severe iron deficiency would likely still be treated initially with a high-dose course of an agent like iron sucrose to fill iron stores. Once stable, that patient could then be transitioned to FPC for long-term physiological maintenance, leveraging its favorable safety profile and ESA-sparing benefits.

11.3 Unanswered Questions and Future Directions

Despite its clear niche, several knowledge gaps remain, pointing to potential avenues for future research that could expand FPC's utility.

• Comparative Long-Term Outcomes: There is a need for large-scale, head-to-head clinical trials comparing FPC directly against other IV iron agents. The primary endpoints of such studies should not be limited to hemoglobin and ESA use but should include long-term cardiovascular outcomes, rates of infection, and validated biomarkers of inflammation and oxidative stress.
• Expansion to Other Populations: While initial forays were unsuccessful, the theoretical benefit of bypassing the hepcidin block remains compelling. Further studies could explore FPC's utility in other chronic inflammatory states associated with functional iron deficiency, such as inflammatory bowel disease, rheumatoid arthritis, or heart failure.
• Home and Peritoneal Dialysis: Investigating novel formulations or administration protocols that could make FPC therapy viable and safe for patients on home hemodialysis or peritoneal dialysis would significantly expand its addressable market.

11.4 Final Conclusion

Ferric Pyrophosphate Citrate is a sophisticated and mechanistically elegant therapeutic agent born from a deep understanding of the specific pathophysiology of anemia in hemodialysis-dependent chronic kidney disease. It is not a universal iron replacement product but a precisely targeted tool. Its innovation lies in its "maintenance over repletion" philosophy, its physiological delivery system that bypasses the hepcidin block, and its demonstrated ability to spare the use of higher-risk ESAs. While its global regulatory footprint is currently limited, its success in the U.S. market validates its clinical value in a complex and vulnerable patient population. The future of FPC will be defined by its ability to generate robust, long-term comparative outcomes data and to potentially translate its unique mechanism of action into tangible benefits for patients beyond the in-center hemodialysis clinic.

Works cited

1. Ferric pyrophosphate citrate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/drugs/DB13995
2. Ferric pyrophosphate citrate - brand name list from Drugs.com, accessed September 24, 2025, https://www.drugs.com/ingredient/ferric-pyrophosphate-citrate.html
3. Ferric pyrophosphate citrate (intravenous route) - Side effects & uses - Mayo Clinic, accessed September 24, 2025, https://www.mayoclinic.org/drugs-supplements/ferric-pyrophosphate-citrate-intravenous-route/description/drg-20487063
4. Ferric Pyrophosphate Citrate - Memorial Sloan Kettering Cancer Center, accessed September 24, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/ferric-pyrophosphate-citrate
5. Ferric Pyrophosphate (Triferic, Triferic Avnu) - PA Health & Wellness, accessed September 24, 2025, https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/Ferric%20Pyrophosphate%20(Triferic,%20Triferic%20Avnu)%20v1.2024.pdf
6. Ferric Pyrophosphate Citrate - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 24, 2025, https://synapse.patsnap.com/drug/3379bcebbbfb4d6bb9e6bc30ed4d4277
7. Ferric Pyrophosphate Citrate - West Bengal Chemical Industries Limited, accessed September 24, 2025, https://www.wbcil.com/iron/ferric-pyrophosphate-citrate/
8. Ferric pyrophosphate citrate - New Drug Approvals, accessed September 24, 2025, https://newdrugapprovals.org/2021/09/16/ferric-pyrophosphate-citrate/
9. Ferric Pyrophosphate Citrate | C18H24Fe4O42P6 | CID 109374151 - PubChem, accessed September 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ferric-Pyrophosphate-Citrate
10. Ferric Pyrophosphate Citrate - Global Calcium Pvt Ltd, accessed September 24, 2025, https://www.globalcalcium.com/products/ferric-pyrophosphate-citrate
11. Ferric Pyrophosphate Citrate MSDS | Safety Data Sheet - West Bengal Chemical Industries Limited, accessed September 24, 2025, https://www.wbcil.com/wp-content/uploads/2023/10/MSDS-of-Ferric-Pyrophosphate-Citrate.pdf
12. CAS 1802359-96-1 Ferric pyrophosphate citrate - Ligands, accessed September 24, 2025, https://complexes.alfa-chemistry.com/product/ferric-pyrophosphate-citrate-cas-1802359-96-1-357704.html?nid=5199
13. Ferric pyrophosphate citrate - KEGG DRUG, accessed September 24, 2025, https://www.genome.jp/dbget-bin/www_bget?dr:D10933
14. Physicochemical characterization of ferric pyrophosphate citrate - PMC, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6245090/
15. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers - PMC, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5324677/
16. Fexeric | European Medicines Agency (EMA), accessed September 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/fexeric
17. Fexeric, common name-ferric citrate coordination complex - PharmaCompass.com, accessed September 24, 2025, https://www.pharmacompass.com/pdf/news/keryxs-fexeric-approved-in-eu-for-hyperphosphatemia-1443869164.pdf
18. Xoanacyl | European Medicines Agency (EMA), accessed September 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/xoanacyl
19. AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - FirstWord Pharma, accessed September 24, 2025, https://firstwordpharma.com/story/5973013
20. TRIFERIC - FDA, accessed September 24, 2025, https://www.fda.gov/media/133022/download
21. Ferric pyrophosphate citrate: interactions with transferrin - PMC - PubMed Central, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6245029/
22. Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients - BioSpace, accessed September 24, 2025, https://www.biospace.com/rockwell-medical-inc-receives-fda-approval-for-triferic-avnu-ferric-pyrophosphate-citrate-intravenous-formulation-of-triferic-for-replacement-of-iron-and-maintenance-of-hemoglobin-in-hemodialysis-patients
23. Ferric pyrophosphate: good things come to those who wait? - PMC, accessed September 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4832995/
24. Showing BioInteractions for Ferric pyrophosphate citrate (DB13995) | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/drugs/DB13995/biointeractions
25. TRIFERIC AVNU® (ferric pyrophosphate citrate injection), for intravenous use - accessdata.fda.gov, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212860s000lbl.pdf
26. triferic avnu - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212860Orig1s001lbl.pdf
27. Reference ID: 4241820 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206317s010lbl.pdf
28. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients - PubMed, accessed September 24, 2025, https://pubmed.ncbi.nlm.nih.gov/26154926/
29. Ferric pyrophosphate citrate Completed Phase 1 Trials for Iron-refractory, Iron-deficiency Anemia (IRIDA) Treatment - DrugBank, accessed September 24, 2025, https://go.drugbank.com/drugs/DB13995/clinical_trials?conditions=DBCOND0086125&phase=1&purpose=treatment&status=completed
30. Ferric pyrophosphate citrate Terminated Phase 2 Trials for Iron-refractory, Iron-deficiency Anemia (IRIDA) Treatment - DrugBank, accessed September 24, 2025, https://go.drugbank.com/drugs/DB13995/clinical_trials?conditions=DBCOND0086125&phase=2&purpose=treatment&status=terminated
31. Reference ID: 4241829 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208551s005lbl.pdf
32. 1 INDICATIONS AND USAGE 1.1 Limitation of Use - accessdata.fda.gov, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208551s000lbl.pdf
33. Triferic (ferric pyrophosphate): Uses, Side Effects, Dosage & Reviews - GoodRx, accessed September 24, 2025, https://www.goodrx.com/triferic/what-is
34. Luis Caveda Senior Director of Regulatory Affairs Rockwell Medical, Inc 30142 South Wixom Road Wixom, MI 48393 RE: NDA 206317; - FDA, accessed September 24, 2025, https://www.fda.gov/media/133021/download
35. Triferic AVNU - ferric pyrophosphate IV (Rx) - Medscape Reference, accessed September 24, 2025, https://reference.medscape.com/drug/triferic-avnu-ferric-pyrophosphate-4000092
36. Ferric pyrophosphate Disease Interactions - Drugs.com, accessed September 24, 2025, https://www.drugs.com/disease-interactions/ferric-pyrophosphate.html
37. CP.PHAR.624 Ferric Pyrophosphate Citrate (Triferic, Triferic Avnu) - Superior Health Plan, accessed September 24, 2025, https://www.superiorhealthplan.com/content/dam/centene/Superior/Provider/pharmacy-policies/CP.PHAR.624.pdf
38. These highlights do not include all the information needed to use TRIFERIC safely and effectively. See full prescribing informat - DailyMed, accessed September 24, 2025, https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=46ec9233-4063-4c48-e054-00144ff8d46c&type=pdf
39. Triferic - Drug Summary, accessed September 24, 2025, https://www.pdr.net/drug-summary/Triferic-ferric-pyrophosphate-citrate-3682
40. Triferic Dosage Guide - Drugs.com, accessed September 24, 2025, https://www.drugs.com/dosage/triferic.html
41. Triferic Avnu Dosage Guide - Drugs.com, accessed September 24, 2025, https://www.drugs.com/dosage/triferic-avnu.html
42. Ferric Pyrophosphate Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 24, 2025, https://www.drugs.com/sfx/ferric-pyrophosphate-side-effects.html
43. Triferic AVNU (Ferric Pyrophosphate Citrate Injection): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 24, 2025, https://www.rxlist.com/triferic-avnu-drug.htm
44. Black Box Warning for Erythropoiesis-Stimulating Agents - Medscape, accessed September 24, 2025, https://www.medscape.com/viewarticle/553499
45. The FDA Black Box Warning for ESAs - American Association of Kidney Patients, accessed September 24, 2025, https://aakp.org/the-fda-black-box-warning-for-esas/
46. Triferic Uses, Side Effects & Warnings - Drugs.com, accessed September 24, 2025, https://www.drugs.com/mtm/triferic.html
47. Ferric pyrophosphate citrate () Advanced Patient Information - Drugs.com, accessed September 24, 2025, https://www.drugs.com/cons/ferric-pyrophosphate-citrate.html
48. Ferric Pyrophosphate IV: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 24, 2025, https://www.rxlist.com/ferric_pyrophosphate_iv/generic-drug.htm
49. Triferic AVNU Advanced Patient Information - Drugs.com, accessed September 24, 2025, https://www.drugs.com/cons/triferic-avnu.html
50. Ferric Pyrophosphate Citrate Solution for Hemodialysis - Cleveland Clinic, accessed September 24, 2025, https://my.clevelandclinic.org/health/drugs/20002-ferric-pyrophosphate-citrate-solution-for-hemodialysis
51. Ferric pyrophosphate: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09147
52. go.drugbank.com, accessed September 24, 2025, https://go.drugbank.com/drugs/DB09147#:~:text=Delafloxacin-,Ferric%20pyrophosphate%20can%20cause%20a%20decrease%20in%20the%20absorption%20of,potentially%20a%20decrease%20in%20efficacy.&text=Demeclocycline%20can%20cause%20a%20decrease,potentially%20a%20decrease%20in%20efficacy.
53. Ferric pyrophosphate Interactions - Drugs.com, accessed September 24, 2025, https://www.drugs.com/drug-interactions/ferric-pyrophosphate.html
54. Ferric citrate Interactions - Drugs.com, accessed September 24, 2025, https://www.drugs.com/drug-interactions/ferric-citrate.html
55. 212860Orig1s000 | FDA, accessed September 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212860Orig1s000MedR.pdf
56. EMEA-002261-PIP01-17 - paediatric investigation plan - European Medicines Agency, accessed September 24, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002261-pip01-17
57. KERYX RECEIVES EUROPEAN APPROVAL FOR FEXERIC(R) (FERRIC CITRATE COORDINATION COMPLEX) FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN ADULTS WITH CHRONIC KIDNEY DISEASE | Fierce Pharma, accessed September 24, 2025, https://www.fiercepharma.com/pharma/keryx-receives-european-approval-for-fexeric-r-ferric-citrate-coordination-complex-for
58. Substances that may be used in Listed medicines in Australia - Therapeutic Goods Administration (TGA), accessed September 24, 2025, https://www.tga.gov.au/sites/default/files/cm-listed-substances_0.pdf
59. IRON GUMMIES (464658) - Therapeutic Goods Administration (TGA), accessed September 24, 2025, https://www.tga.gov.au/resources/artg/464658